PRESS RELEASES

Date Title and Summary View
May 4, 2017
Summary ToggleZafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
- Clinical Trial Shows Weight Loss Trends of Up to One Pound Per Week and an Early Favorable Safety and Tolerability Profile - - Improvements in Metabolic Parameters and Trends for Weight Loss Supportive of Drug Effect - - Results Support Advancement to Phase 2 Clinical Trial in Patients with Type
Summary ToggleZafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
Mar 9, 2017
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2016 Financial Results
BOSTON, March 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, today announced its fourth quarter and full year 2016 financial results. ...
Summary ToggleZafgen Reports Fourth Quarter and Full Year 2016 Financial Results
Mar 2, 2017
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
BOSTON, March 02, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that it will host a conference call on
Summary ToggleZafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial Results
Feb 28, 2017
Summary ToggleZafgen to Present at Upcoming Investor Conferences
BOSTON, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and
Summary ToggleZafgen to Present at Upcoming Investor Conferences
Feb 9, 2017
Summary ToggleZafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
BOSTON, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and
Summary ToggleZafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference
Nov 9, 2016
Summary ToggleZafgen Reports Third Quarter 2016 Financial Results

-Advancing Phase 1 Clinical Trial of ZGN-1061; Top-Line Results Expected First Quarter 2017-

Summary ToggleZafgen Reports Third Quarter 2016 Financial Results
Sep 20, 2016
Summary ToggleZafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061

Company Expects to Report Data by End of First Quarter 2017

Summary ToggleZafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061
Aug 4, 2016
Summary ToggleZafgen Reports Second Quarter 2016 Financial Results
BOSTON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its second quarter 2016 financial results.
Summary ToggleZafgen Reports Second Quarter 2016 Financial Results
Aug 3, 2016
Summary ToggleZafgen to Present at Canaccord Genuity's 36th Annual Growth Conference
BOSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, President and Chief Executive Officer
Summary ToggleZafgen to Present at Canaccord Genuity's 36th Annual Growth Conference
Jul 19, 2016
Summary ToggleZafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
-ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical Development Priorities- -Strong Cash Position Sufficient to Fund Operations through Phase 2a Clinical Trials
Summary ToggleZafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061